CHO Plus Secures U.S. Patent for Engineered Yeast Cell Technology to Boost Protein Production
核心洞察
CHO Plus (搜索), Inc. has received U.S. Patent No. 12,404,502 for a novel technology that fuses yeast cells to create hybrid cells producing more recombinant protein per cell.
The patented process involves sorting hybrid cells for high levels of endoplasmic reticulum (搜索), the cellular machinery crucial for protein synthesis.
The company's engineered CHO cells demonstrate up to 10-fold higher therapeutic antibody production compared to unengineered cells, while engineered HEK-293 cells produce up to 20-fold more AAV vectors (搜索).
CHO Plus (搜索), Inc., a leading developer of biopharmaceutical manufacturing technology, has been awarded U.S. Patent No. 12,404,502 by the United States Patent and Trademark Office for an innovative technology that significantly enhances protein production in yeast cells. The patent covers a groundbreaking method for fusing yeast cells to create hybrid cells that produce substantially more recombinant protein per cell.
Novel Cell Fusion Technology
The patented technology involves fusing yeast cells together to generate hybrid cells with enhanced protein production capabilities. After fusion, these hybrid cells undergo sorting for high levels of endoplasmic reticulum (搜索), the subcellular machinery essential for protein synthesis. The patent provides comprehensive protection for both the process of obtaining these engineered cells and their composition as a matter.
Larry Forman, CHO Plus (搜索) Founder, CEO, and inventor of the technology, commented: "We continue to develop and build out our cell engineering technologies. Now we have an offering that could improve productivity for food ingredients and other industrial products via engineered yeast cells."
Broad Applications Across Industries
The engineered yeast technology has wide-ranging applications across multiple sectors. In the food industry, yeast is utilized to produce recombinant substitutes for egg proteins such as ovalbumin, milk proteins including casein, and flavor enhancers like leghemoglobin and myoglobin. The pharmaceutical industry employs yeast for manufacturing therapeutic agents including insulin and vaccines (搜索). Additional applications extend to industrial silk production, metal-binding proteins, enzymes like amylase, and industrial fermentation processes.
Proven Performance in Mammalian Cell Engineering
CHO Plus (搜索) has demonstrated significant success with its mammalian cell engineering technologies. Recent results show that the company's engineered CHO cells produce up to 10-fold more therapeutic antibodies compared to unengineered cells. Additionally, their engineered HEK-293 cells generate up to 20-fold more AAV vectors (搜索), achieving up to 55% full capsids before purification.
Strategic Partnership Opportunities
The company is actively seeking strategic partnerships to advance this technology. "We continue to attract interest in our mammalian cell technologies, such as for CHO cells and HEK-293 cells. This patent represents a new opportunity, and we seek a major funding and technology partner to take the lead in using engineered yeast cells for food or pharmaceutical production," Forman stated.
With a focus on innovation and collaboration, CHO Plus (搜索) is committed to advancing the production of therapeutic proteins and gene therapy vectors to address a wide range of clinical conditions. The company, founded with the mission of increasing productivity of cells used for manufacturing life-saving therapeutic agents, has developed cutting-edge technologies for creating high-productivity GMP-compliant mammalian cell lines and holds patents granted and pending for several technologies across more than ten jurisdictions worldwide.